WP_Query Object
(
[query] => Array
(
[post_type] => post
[posts_per_page] => 3
[post_status] => publish
[orderby] => rand
)
[query_vars] => Array
(
[post_type] => post
[posts_per_page] => 3
[post_status] => publish
[orderby] => rand
[error] =>
[m] =>
[p] => 0
[post_parent] =>
[subpost] =>
[subpost_id] =>
[attachment] =>
[attachment_id] => 0
[name] =>
[pagename] =>
[page_id] => 0
[second] =>
[minute] =>
[hour] =>
[day] => 0
[monthnum] => 0
[year] => 0
[w] => 0
[category_name] =>
[tag] =>
[cat] =>
[tag_id] =>
[author] =>
[author_name] =>
[feed] =>
[tb] =>
[paged] => 0
[meta_key] =>
[meta_value] =>
[preview] =>
[s] =>
[sentence] =>
[title] =>
[fields] => all
[menu_order] =>
[embed] =>
[category__in] => Array
(
)
[category__not_in] => Array
(
)
[category__and] => Array
(
)
[post__in] => Array
(
)
[post__not_in] => Array
(
)
[post_name__in] => Array
(
)
[tag__in] => Array
(
)
[tag__not_in] => Array
(
)
[tag__and] => Array
(
)
[tag_slug__in] => Array
(
)
[tag_slug__and] => Array
(
)
[post_parent__in] => Array
(
)
[post_parent__not_in] => Array
(
)
[author__in] => Array
(
)
[author__not_in] => Array
(
)
[search_columns] => Array
(
)
[ignore_sticky_posts] =>
[suppress_filters] =>
[cache_results] => 1
[update_post_term_cache] => 1
[update_menu_item_cache] =>
[lazy_load_term_meta] => 1
[update_post_meta_cache] => 1
[nopaging] =>
[comments_per_page] => 50
[no_found_rows] =>
[order] =>
)
[tax_query] => WP_Tax_Query Object
(
[queries] => Array
(
)
[relation] => AND
[table_aliases:protected] => Array
(
)
[queried_terms] => Array
(
)
[primary_table] => wp_posts
[primary_id_column] => ID
)
[meta_query] => WP_Meta_Query Object
(
[queries] => Array
(
)
[relation] =>
[meta_table] =>
[meta_id_column] =>
[primary_table] =>
[primary_id_column] =>
[table_aliases:protected] => Array
(
)
[clauses:protected] => Array
(
)
[has_or_relation:protected] =>
)
[date_query] =>
[request] => SELECT SQL_CALC_FOUND_ROWS wp_posts.ID
FROM wp_posts
WHERE 1=1 AND wp_posts.post_type = 'post' AND ((wp_posts.post_status = 'publish'))
ORDER BY RAND()
LIMIT 0, 3
[posts] => Array
(
[0] => WP_Post Object
(
[ID] => 4906
[post_author] => 4
[post_date] => 2025-07-17 10:27:09
[post_date_gmt] => 2025-07-17 14:27:09
[post_content] =>
The Redesignation brings $10 million in funding to drive innovation, company formation, and economic growth.
The Center for Biotechnology (CFB) has announced its re-designated as a Center for Advanced Technology (CAT) by Empire State Development's Division of Science, Technology and Innovation (NYSTAR), a recognition that comes with $1 million in annual funding over the next ten years. The $10 million commitment underscores the CFB’s leadership in accelerating life science innovation, supporting early-stage technology development, and fueling economic growth through start-up formation and industry partnerships.
“The Center for Biotechnology has served as a critical bridge between academic research and commercial success,” said Dr. Clinton Rubin, Director of the Center for Biotechnology. “This re-designation ensures we can continue to expand our impact, helping innovators bring breakthrough technology to market and strengthening New York’s position as a leader in the bioscience industry.”
Empire State Development President, CEO and Commissioner Hope Knight said, “NYSTAR’s Centers for Advanced Technology are vital to our strategic efforts to grow New York’s economy and the state’s greater innovation ecosystem. By investing in the industries of tomorrow, New Yorkers benefit today through dynamic partnerships that help to create new jobs, generate more revenues, and encourage more companies to establish a footprint in communities all throughout the state.”
The Center for Biotechnology is located on the campus of Stony Brook University (SBU), the flagship research institution within the prestigious State University of New York (SUNY) system. Stony Brook University is recognized as a national and global leader in life sciences research, biomedical innovation, and clinical care. Situated on Long Island, New York, Stony Brook has built a formidable reputation as a hub for cutting-edge scientific discovery and translational medicine. The Center for Biotechnology builds upon these strengths by providing cutting-edge programming and competitive financial support to advance biomedical innovation and emerging company growth.
“We are excited to build upon the successful foundation of strong entrepreneurial networks, infrastructure, and programming that we have built over the last four decades” said Dr. Diane Fabel, Chief Operating Officer at the Center for Biotechnology. “The impacts we have had during our last designation period include over $1B in total economic impact with more than 1000 jobs created, and driving more than $315M in follow-on funding. We are excited to see those numbers continue to grow when we celebrate fifty years of hard work at the end of this redesignation period”.
As part of the New York State CAT program, the CFB will continue to work with emerging and established companies across the state to de-risk early-stage technologies, advance both technology and company value, foster public-private collaboration, and provide critical infrastructure for the region’s growing life science ecosystem. Additionally, the CFB team will continue its efforts to develop a life sciences workforce to support the region's bio-innovation economy with a specific emphasis on sectors deemed important to the NYS economy.
Dowload the full press release here.
[post_title] => Center for Biotechnology Announces Redesignation as New York State Center for Advanced Technology
[post_excerpt] =>
[post_status] => publish
[comment_status] => open
[ping_status] => open
[post_password] =>
[post_name] => redesignation2025
[to_ping] =>
[pinged] =>
[post_modified] => 2025-07-21 14:51:44
[post_modified_gmt] => 2025-07-21 18:51:44
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://centerforbiotechnology.org/?p=4906
[menu_order] => 0
[post_type] => post
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[1] => WP_Post Object
(
[ID] => 4488
[post_author] => 4
[post_date] => 2024-10-24 10:45:00
[post_date_gmt] => 2024-10-24 14:45:00
[post_content] =>
Governor Kathy Hochul has unveiled plans for New York BioGenesis Park, a groundbreaking $430 million Cell and Gene Therapy (CGT) Innovation Hub in Nassau County, Long Island. To be developed by The Albanese Organization, Inc., this state-of-the-art facility would catalyze CGT research, development, clinical manufacturing, and commercialization across New York State. With a historic $150 million state investment—the largest nationwide for a cell and gene therapy hub—NYBGP would accelerate the delivery of new therapies from lab to patient in New York's diverse communities. This transformative hub aims to establish New York as the leading global destination for CGT innovation, driving economic growth, attracting top talent, and revolutionizing patient care statewide and beyond.
The Center for Biotechnology is thrilled to be counted as a partner in this effort, and is looking forward to working with our colleagues in the initiative to help catalyze and accelerate life-changing therapies.
New York BioGenesis Park is envisioned as a cutting-edge, full-service campus dedicated to advancing cell and gene therapies and accelerating their commercialization. At full build-out, the 700,000-square-foot park would create an end-to-end Cell and Gene Therapy innovation and supply center, featuring interconnected areas for public engagement, research, manufacturing, and collaboration.
A cornerstone of New York BioGenesis Park is its incubator, supported by a $50 million investment from ESD's Long Island Investment Fund. This facility will empower early-stage therapeutic developers by offering state-of-the-art wet lab space, shared equipment, office space, and other essential resources. This nurturing environment will provide Cell and Gene Therapy companies with access to specialized equipment, mentoring, and stage-appropriate financial guidance. As a critical component of New York BioGenesis Park, the incubator is poised to catalyze the growth of promising Cell and Gene Therapy companies by providing them with resources and support, unlocking their potential for innovation and success.
New York BioGenesis Park would foster strong ties with academic and medical institutions throughout New York, creating a robust ecosystem for Cell and Gene Therapy innovation. Collaborating with the Empire State Cellular Therapy Consortium and world-class institutions like Cold Spring Harbor Laboratory, the Feinstein Institutes, Northwell Health, Roswell Park, Stony Brook University, Weill Cornell, Columbia University and others around the state, New York BioGenesis Park would enhance research synergies and accelerate medical breakthroughs. This ecosystem would bring together experts in advanced Cell and Gene Therapy therapies, offering specialized facilities, services, and resources to both tenants and collaborating institutions. By facilitating cutting-edge science, innovative technology development and novel approaches to clinical trials, New York BioGenesis Park would ensure New York's institutions remain globally competitive in groundbreaking Cell and Gene Therapy research and commercialization.
Read the press release of Governor Hochul's announcement here:
https://www.governor.ny.gov/news/governor-hochul-launches-next-phase-long-islands-nation-leading-cell-and-gene-therapy
[post_title] => Long Island to be location for Nation-Leading Cell and Gene Therapy Innovation Hub: New York BioGenesis Park.
[post_excerpt] =>
[post_status] => publish
[comment_status] => open
[ping_status] => open
[post_password] =>
[post_name] => long-island-to-be-location-for-nation-leading-cell-and-gene-therapy-innovation-hub-new-york-biogenesis-park
[to_ping] =>
[pinged] =>
[post_modified] => 2025-02-26 16:35:20
[post_modified_gmt] => 2025-02-26 21:35:20
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://centerforbiotechnology.org/?p=4488
[menu_order] => 0
[post_type] => post
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[2] => WP_Post Object
(
[ID] => 3826
[post_author] => 4
[post_date] => 2021-09-20 16:07:19
[post_date_gmt] => 2021-09-20 16:07:19
[post_content] =>
Led by experts from BBC Entrepreneurial Training & Consulting, join our live Virtual Classroom for an interactive, 2 day SBIR/STTR workshop. We’ll review the basics including program purpose; eligibility; and sources of funding. Then we’ll provide proposal prep essentials of the NIH and NSF programs. In addition to up-to-date information on the SBIR/STTR programs, we will cover:
- NIH and NSF grant mechanisms and where to find them
- How to find the program officers, how to approach them, what questions to ask
- How to do research using the web tools available (eReporter, SBIR.gov, etc.)
- Common pitfalls and how to avoid them, and much more.
Workshop registration fee: $25.00. Please register online: https://cfbsbirtrain2021b.eventbrite.com
Workshop is produced by the Center for Biotechnology at Stony Brook University and in partnership with Columbia Technology Ventures.
[post_title] => SBIR/STTR Virtual Workshop 9/28-9/29
[post_excerpt] => The Center for Biotechnology & Columbia Tech Ventures present a 2-day intensive SBIR/STTR workshop.
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => sbir-sttr-virtual-workshop-9-28-9-29
[to_ping] =>
[pinged] =>
[post_modified] => 2021-10-28 13:15:20
[post_modified_gmt] => 2021-10-28 13:15:20
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://centerforbiotechnology.org/?p=3826
[menu_order] => 35
[post_type] => post
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[3] => WP_Post Object
(
[ID] => 2824
[post_author] => 1
[post_date] => 2017-09-20 13:41:33
[post_date_gmt] => 2017-09-20 13:41:33
[post_content] =>
Avanti Biosciences, Inc. a preclinical-stage biopharmaceutical company lead by Center for Biotechnology BioEntrepreneur-in-Residence Dr. Gian Luca Araldi, has announced that the National Institute of Aging (NIA) has awarded the Company an SBIR fast-track grant of up to $1,930,000 to support the company’s small molecule treatment for Alzheimer’s disease (AD) over the next 3 years.
The award will enable the preparation and testing of Avanti’s proprietary compounds derivatized from natural catechins, which inhibit DYRK1A, an enzyme that modulates tau phosphorylation. Working with NY Institute for Basic Research and the University of California San Diego (UCSD), the company hopes to attenuate and potentially reverse pathogenesis for Alzheimer’s disease and other neurodegenerative diseases.
“This award marks a significant milestone for Avanti Biosciences and an important step for their research into a treatment for Alzheimer’s disease” stated Dr. Clinton Rubin, Director of the New York State Center for Biotechnology at Stony Brook University. “The Center for Biotechnology is thrilled to see another success for one of the emerging bioscience companies fueling our regional bioecosystem and we proudly support Dr. Araldi’s work as one of our BioEntrepreneurs-in-Residence.”
Dr. Gian Luca Araldi, Founder and Chief Executive Officer of Avanti, stated, “We are delighted to have been granted this funding from the NIA as it underscores the great need for innovative, effective treatments for this disease, and recognizes the potential benefits that our compounds may provide for patients with AD. The continuous support of Center for Biotechnology and the BioEntrepreneur-in-Residence program has been critical force in the development of our technology and the company as whole.”
More than five million people in the United States are living with Alzheimer’s disease, a progressive, irreversible, neurodegenerative disease that destroys memory and other cognitive abilities. It is the sixth leading cause of death in the United States and as the aging population in the country grows, the incidence rate is expected to rise dramatically.
Learn more about Avanti Biosciences:
avantibiosciences.com
[post_title] => CFB BEIR Receives $1.9M SBIR Fast-Track
[post_excerpt] => Avanti Biosciences, Inc. a preclinical-stage biopharmaceutical company lead by CFB BioEntrepreneur-in-Residence Dr. Gian Luca Araldi, has announced that the National Institute of Aging (NIA) has awarded the Company an SBIR fast-track grant of up to $1,930,000 to support the company’s small molecule Alzheimer’s disease (AD) over the next 3 years.
[post_status] => publish
[comment_status] => open
[ping_status] => open
[post_password] =>
[post_name] => cfb-beir-receives-1-9m-sbir-fast-track
[to_ping] =>
[pinged] =>
[post_modified] => 2018-01-23 14:39:07
[post_modified_gmt] => 2018-01-23 14:39:07
[post_content_filtered] =>
[post_parent] => 0
[guid] => http://centerforbiotechnology.org/?p=2824
[menu_order] => 138
[post_type] => post
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[4] => WP_Post Object
(
[ID] => 3046
[post_author] => 3
[post_date] => 2018-08-22 20:10:08
[post_date_gmt] => 2018-08-22 20:10:08
[post_content] =>
Seasoned Industry Veterans Join Long Island Bioscience Hub’s BioEntrepreneur-in Residence Initiative
The
Long Island Bioscience Hub, a collaboration between Stony Brook University, Brookhaven National Laboratory, Cold Spring Harbor Laboratory, and the Feinstein Institute at Northwell Health, announced the appointment of Dr. Boris Shor and Mr. Peter Young as its newest BioEntrepreneurs-In-Residence (BEIRs). Dr. Shor and Mr. Young have extensive bioscience industry experience affording them unique perspectives in the role of Bio Entrepreneur-in-Residence. Each will work with the Center for Biotechnology to identify commercially promising academic technologies that have the potential to support company formation.
Dr. Shor has nearly 15 years of experience in leading oncology programs and external R&D partnerships at the large pharmas and biotech companies, with specific focus on preclinical development of small molecule kinase inhibitors and biologics. Previously at Pfizer, Dr. Shor led internal and external collaboration project teams to develop novel antibody-drug conjugates and supported BLA filing for Inotuzumab, which was approved for the treatment of leukemia in 2017. Prior to that, he was a project team leader at the Oncology Unit of Wyeth, managing the discovery of novel kinase inhibitors for the treatment of cancer. He currently serves on the executive management team of early-stage biotech companies and is a founder of BioIDEA, a biotech pitch event in New York City. Dr. Shor received a Ph.D. in Molecular and Cell Biology at the State University of New York Downstate Medical Center and performed a postdoctoral fellowship in the Inflammation Research team at Johnson & Johnson Pharmaceutical R&D prior to joining Pfizer.
Mr. Young is an experienced life science industry consultant with over thirty-five years experience and currently serves as an executive-in-residence with Pappas Capital, where he leads the firm’s initiatives in translational research. He also serves on the Oversight Committee for the University of Miami Wallace H. Coulter Center for Translational Research and the Long Island Bioscience Hub External Review Board. He is a past member of the BIO board and chairman of NCBIO, the North Carolina industry trade association. Mr. Young earned a BA in History and an MBA from Indiana University.
“We couldn’t be more delighted to add Boris and Peter to the Center for Biotechnology’s roster of BioEntrepreneurs-in-Residence. The ongoing expansion of the BioEntrepreneur-in-Residence program is critical for the continued development of the bioscience industry in the region” Diane Fabel, Director of Operations at the Center for Biotechnology said. “The attraction and retention of skilled bioscience management talent is an important component of ensuring companies can be launched and also grow here.”
“I am thrilled to join the Center for Biotechnology as a BioEntrepreneur-in-Residence” Dr. Shor stated, “and I have already begun the work of assessing technologies and building a company. I appreciate the resources the Center for Biotechnology offers through their many programs not only to me, but to emerging companies throughout New York.”
“Having worked with the Center for Biotechnology as an advisor for several years, I am pleased to formally join the Center as BioEntrepreneur-in-Residence” Peter Young stated. “There is an incredible amount of activity related to bioscience development currently taking place right now in the region, and the Center's many entrepreneurial programs provide a great springboard for significant industry expansion - I'm thrilled to be a part of it.”
In their roles as BEIRs, Dr. Shor and Mr. Young will work to identify a technology or technologies from within partner institutions that will create the foundation for licensing and company formation. They will have the support of the Center for Biotechnology business and technology development staff, as well as the support of external industry advisors to develop successful commercialization strategies. Ultimately, the goal is to help the company position itself prepare for SBIR/STTR grant opportunities, and Angel and VC investment.
Dr. Shor and Mr. Young join the eight BEIRs already working with the Center for Biotechnology who collectively have launched ten new companies in the last five years.
[post_title] => Long Island Bioscience Hub Appoints Additional BioEntrepreneurs-In-Residence
[post_excerpt] => Seasoned Industry Veterans Join Long Island Bioscience Hub’s BioEntrepreneur-in-Residence Initiative
[post_status] => publish
[comment_status] => open
[ping_status] => open
[post_password] =>
[post_name] => libh-beir-2018
[to_ping] =>
[pinged] =>
[post_modified] => 2018-08-22 20:10:08
[post_modified_gmt] => 2018-08-22 20:10:08
[post_content_filtered] =>
[post_parent] => 0
[guid] => http://centerforbiotechnology.org/?p=3046
[menu_order] => 114
[post_type] => post
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
)
[post_count] => 5
[current_post] => -1
[before_loop] => 1
[in_the_loop] =>
[post] => WP_Post Object
(
[ID] => 4906
[post_author] => 4
[post_date] => 2025-07-17 10:27:09
[post_date_gmt] => 2025-07-17 14:27:09
[post_content] =>
The Redesignation brings $10 million in funding to drive innovation, company formation, and economic growth.
The Center for Biotechnology (CFB) has announced its re-designated as a Center for Advanced Technology (CAT) by Empire State Development's Division of Science, Technology and Innovation (NYSTAR), a recognition that comes with $1 million in annual funding over the next ten years. The $10 million commitment underscores the CFB’s leadership in accelerating life science innovation, supporting early-stage technology development, and fueling economic growth through start-up formation and industry partnerships.
“The Center for Biotechnology has served as a critical bridge between academic research and commercial success,” said Dr. Clinton Rubin, Director of the Center for Biotechnology. “This re-designation ensures we can continue to expand our impact, helping innovators bring breakthrough technology to market and strengthening New York’s position as a leader in the bioscience industry.”
Empire State Development President, CEO and Commissioner Hope Knight said, “NYSTAR’s Centers for Advanced Technology are vital to our strategic efforts to grow New York’s economy and the state’s greater innovation ecosystem. By investing in the industries of tomorrow, New Yorkers benefit today through dynamic partnerships that help to create new jobs, generate more revenues, and encourage more companies to establish a footprint in communities all throughout the state.”
The Center for Biotechnology is located on the campus of Stony Brook University (SBU), the flagship research institution within the prestigious State University of New York (SUNY) system. Stony Brook University is recognized as a national and global leader in life sciences research, biomedical innovation, and clinical care. Situated on Long Island, New York, Stony Brook has built a formidable reputation as a hub for cutting-edge scientific discovery and translational medicine. The Center for Biotechnology builds upon these strengths by providing cutting-edge programming and competitive financial support to advance biomedical innovation and emerging company growth.
“We are excited to build upon the successful foundation of strong entrepreneurial networks, infrastructure, and programming that we have built over the last four decades” said Dr. Diane Fabel, Chief Operating Officer at the Center for Biotechnology. “The impacts we have had during our last designation period include over $1B in total economic impact with more than 1000 jobs created, and driving more than $315M in follow-on funding. We are excited to see those numbers continue to grow when we celebrate fifty years of hard work at the end of this redesignation period”.
As part of the New York State CAT program, the CFB will continue to work with emerging and established companies across the state to de-risk early-stage technologies, advance both technology and company value, foster public-private collaboration, and provide critical infrastructure for the region’s growing life science ecosystem. Additionally, the CFB team will continue its efforts to develop a life sciences workforce to support the region's bio-innovation economy with a specific emphasis on sectors deemed important to the NYS economy.
Dowload the full press release here.
[post_title] => Center for Biotechnology Announces Redesignation as New York State Center for Advanced Technology
[post_excerpt] =>
[post_status] => publish
[comment_status] => open
[ping_status] => open
[post_password] =>
[post_name] => redesignation2025
[to_ping] =>
[pinged] =>
[post_modified] => 2025-07-21 14:51:44
[post_modified_gmt] => 2025-07-21 18:51:44
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://centerforbiotechnology.org/?p=4906
[menu_order] => 0
[post_type] => post
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[comment_count] => 0
[current_comment] => -1
[found_posts] => 281
[max_num_pages] => 94
[max_num_comment_pages] => 0
[is_single] =>
[is_preview] =>
[is_page] =>
[is_archive] =>
[is_date] =>
[is_year] =>
[is_month] =>
[is_day] =>
[is_time] =>
[is_author] =>
[is_category] =>
[is_tag] =>
[is_tax] =>
[is_search] =>
[is_feed] =>
[is_comment_feed] =>
[is_trackback] =>
[is_home] => 1
[is_privacy_policy] =>
[is_404] =>
[is_embed] =>
[is_paged] =>
[is_admin] =>
[is_attachment] =>
[is_singular] =>
[is_robots] =>
[is_favicon] =>
[is_posts_page] =>
[is_post_type_archive] =>
[query_vars_hash:WP_Query:private] => 325c4f9f1aebaa5ec90666fa54175ba0
[query_vars_changed:WP_Query:private] =>
[thumbnails_cached] =>
[allow_query_attachment_by_filename:protected] =>
[stopwords:WP_Query:private] =>
[compat_fields:WP_Query:private] => Array
(
[0] => query_vars_hash
[1] => query_vars_changed
)
[compat_methods:WP_Query:private] => Array
(
[0] => init_query_flags
[1] => parse_tax_query
)
[query_cache_key:WP_Query:private] =>
)
